Specific Accumulation of a Cell Penetrating Peptide Targeting AAC-11 in Melanoma Tumors

Melanoma is the most serious and potentially dangerous form of skin cancer with a rapid increase in prevalence, especially among western countries. The prognosis for patients with the more advanced form of the disease, metastatic melanoma, remains poor with survival rates ranging from 6.7% to 8% at 5 years, and a median survival of 6 to 9 months. Therefore, there is a clear unmet clinical need to identify new drugs to combat melanoma.

Author(s):

Ewa Kotula, Léonard Jagot-Lacoussiere, Heriberto Bruzzoni-Giovanelli and Jean-Luc Poyet

Abstract | Full-Text | PDF

Share this